Catalog Advanced Search

Search by Category
Search by Format
Sort By
Search by Type
Search by Category
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Product not yet rated Contains 2 Component(s)

    Webinar hosted by the Women's Initiatives Committee on Tuesday, December 13, 2022.

    The purpose of this webinar is to discuss the issues facing women who wish to pursue an academic career in Hepatology. The idea behind is that examining the obstacles and the difficulties will help in identifying the possible solutions.

    The webinar will start with the trailer of the very relevant documentary “Picture a Scientist” as an introduction to formal presentations, which will examine the problem of academic disadvantage, both in terms of poor recognition of career progression and authorship. Two lectures will be an exemplification of real careers by a junior and a senior faculty member, and lastly a lecture will be devoted to identify possible resources.

    There will then be a 20-minute discussion between panelists and a Q and A session to involve the audience, directed by our moderator.

    Erica Villa (Moderator)

    Professor of Gastroenterology

    University of Modena and Reggio Emilia

    Tatyana Kushner (Moderator)

    Associate Professor, Division of Liver Diseases

    Icahn School of Medicine at Mount Sinai

    Tatyana Kushner, MD, MSCE, is Assistant Professor in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York. She completed her medical school and internal medicine training at Mount Sinai School of Medicine, a fellowship in gastroenterology and a masters in clinical epidemiology at the University of Pennsylvania, and a fellowship in transplant hepatology at the University of California, San Francisco (UCSF). Her research focuses on both epidemiologic and patient-centered outcomes in viral hepatitis, with an emerging focus in the area of women’s health and pregnancy care, and the goal of developing and studying interventions to improve clinical outcomes in this patient population. She has recently established a Women's Liver Clinic at Mount Sinai in order to enhance the diagnosis and management of liver disease during pregnancy and post-delivery, particularly of hepatitis B and hepatitis C. 

     

    Monika Sarkar (Moderator)

    Marina Berenguer

    Guadalupe Garcia-Tsao

    Guadalupe Garcia-Tsao, MD, FAASLD is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

    Kathleen E. Corey

    Kathleen E. Corey, MD, MPH, MMSc is the Director of the MGH Non-Alcoholic Fatty Liver Disease (NAFLD) Clinic, Associate Program Director for the Medicine Residency for Clinical and Translational Research, a hepatologist who specializes in NAFLD, Physician Investigator in the CTEU, and an Assistant Professor of Medicine at HMS.

     Dr. Corey’s interests include clinical and translational research in NAFLD. She aims to better understand predictors of development and progression of NAFLD, the interplay between cardiovascular disease and NAFLD and the natural history of NAFLD in persons living with HIV (PLWH). She is the Co-PI for an R01 evaluating the role of tesamorelin, a growth hormone-releasing hormone for the treatment of NAFLD and is involved in an NIH-funded study on the prevalence, risk factors and treatment of NAFLD in PLWH.

     Dr. Corey earned her MD at Duke University School of Medicine, her MPH from the University of North Carolina and her MMSc from Harvard Medical School. Prior to joining the faculty of MGH, she completed her training in Internal Medicine, Chief Residency, Gastroenterology and Advanced Hepatology and Liver Transplant at MGH.

    Rotonya Carr, MD

    Anita Chong, PhD

  • Product not yet rated Contains 2 Component(s)

    Webinar hosted by the Hypertension SIG on Monday, December 12, 2022.

    There is emerging data showing benefits of diagnosing clinically significant portal hypertension and its treatment to prevent decompensation. The field is rapidly evolving, specifically with respect to non-invasive modalities of measurement. This webinar will review currently available non-invasive tests to measure clinically significant portal hypertension including blood tests, liver stiffness and spleen stiffness. Use of non-invasive measurements in special populations such as those with fatty liver disease and those who have achieved sustained virological response as well as how to monitor improvements in clinically significant portal hypertension without ongoing injury are also areas of interest which will be addressed.

    There will then be a 20-minute discussion between panelists and a Q and A session to involve the audience, directed by our moderator.

    Maja Thiele, MD, PhD

    Dr. Maja Thiele works to reduce morbidity and mortality from alcohol-related liver disease, for the benefit of an otherwise stigmatized patient group. Her research centers on the development and validation of diagnostic and prognostic biomarkers, with a particular focus on early disease detection, cost-effective referral pathways and omics technologies. Elastography expert contributor to EASL Clinical Practice Guidance, the BAVENO VII consensus statement, and AASLD clinical guidance. Partner in the European research consortia GALAXY, LiverScreen, MicrobPredict and SALVE.

    Annalisa Berzigotti

    Annalisa Berzigotti graduated in Medicine in Bologna, Italy, where she also obtained the title of specialist in Internal Medicine and a Doctorate in ultrasound in medicine. She expanded her knowledge in hepatology at the Hepatic hemodynamic Laboratory of the Liver Unit of the Hospital Clinic, University of Barcelona, Spain, where she obtained a Doctorate in hepatology. In December 2014 she joined the hepatology group of the Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Switzerland. Since March 2021 she is chief of the liver group and ad interim clinic director at the Department of Visceral Surgery and Medicine, Bern University Hospital.  Annalisa Berzigotti has been member of the Governing Board of the European Association for the Study of the Liver in 2016-2019. Since 2022 she is Liver Representative at the United European Gastroenterology (UEG) Council. She is Associate Editor of the Journal of Hepatology and of Seminars in Liver Disease. Her main research interests include portal hypertension and non-invasive assessment of liver disease.

    Atoosa Rabiee, MD

    Annalisa Berzigotti graduated in Medicine in Bologna, Italy, where she also obtained the title of specialist in Internal Medicine and a Doctorate in ultrasound in medicine. She expanded her knowledge in hepatology at the Hepatic hemodynamic Laboratory of the Liver Unit of the Hospital Clinic, University of Barcelona, Spain, where she obtained a Doctorate in hepatology. In December 2014 she joined the hepatology group of the Department of Visceral Surgery and Medicine, Bern University Hospital, University of Bern, Switzerland. Since March 2021 she is chief of the liver group and ad interim clinic director at the Department of Visceral Surgery and Medicine, Bern University Hospital.  Annalisa Berzigotti has been member of the Governing Board of the European Association for the Study of the Liver in 2016-2019. Since 2022 she is Liver Representative at the United European Gastroenterology (UEG) Council. She is Associate Editor of the Journal of Hepatology and of Seminars in Liver Disease. Her main research interests include portal hypertension and non-invasive assessment of liver disease.

  • Product not yet rated Contains 2 Component(s)

    The emerging topic conference occurred on October 1st & 2nd, 2022. After completing this activity, you should be able to: • Define and list disparities that are present in chronic liver disease and liver transplantation. • Construct and design strategies around palliative care implementation in chronic liver disease management. • Develop and present strategies to eliminate disparities in chronic liver disease management.

    There has been increasing national awareness of systemic racism and oppression of communities of color in the United States. Systemic racism negatively impacts health outcomes and has also played a role in decreased access to specialty care, liver transplant waitlist, receipt of liver transplantation and post-transplant outcomes. Patients of color are disproportionately less likely to be listed for liver transplant or to undergo transplantation. This webinar is intended to increase awareness of the barriers patients experience in the liver transplant process and propose strategies to increase access to liver transplant.

  • Contains 9 Component(s)

    Recordings from the AASLD/EASL NAFLD Nomenclature Consensus Conference can be accessed here. The conference took place July 8-9, 2022 in Chicago, IL and virtually.

    Recordings from the AASLD/EASL NAFLD Nomenclature Consensus Conference can be accessed here. The conference took place July 8-9, 2022 in Chicago, IL and virtually.

  • Product not yet rated Contains 2 Component(s)

    Webinar hosted by the Clinical Practice Special Interest Group on Thursday, September 15, 2022.

    Ascites is a common complication and often the first sign of decompensation in patients with End-Stage Liver Disease. Management of ascites is often fraught with complex challenges including electrolyte imbalances, renal failure, hepatic encephalopathy, and significant utilization of resources. A proportion of the patients do not respond to conventional diuretic therapy (refractory ascites) or develop significant side effects that limit the diuretics' optimal dosing, leading to suboptimal control of ascites ( intractable ascites). This webinar will review recent advances in managing refractory/intractable ascites.

  • Contains 2 Component(s)

    Webinar hosted by the Clinical Practice Special Interest Group on Thursday, July 14, 2022.

    Management of autoimmune hepatitis is often quite complex, especially for those not achieving remission with conventional immunosuppression. This webinar aims to review current and upcoming pharmacological treatment options in the management of these special groups of patients.

  • Product not yet rated Contains 7 Component(s)

    The purpose of the AASLD/EASL HBV Endpoints Conference is to bring together the academic, regulatory, pharmaceutical communities and patients’ advocacy groups to discuss therapeutic endpoints, trial designs appropriate patient populations and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D.

    The purpose of the AASLD/EASL HBV Endpoints Conference is to bring together the academic, regulatory, pharmaceutical communities and patients’ advocacy groups to discuss therapeutic endpoints, trial designs appropriate patient populations and safety concerns with regards to novel therapeutic approaches for treatment of chronic hepatitis B and D. The HBV therapeutic field is at a crossroads with many different approaches being considered but numerous regulatory issues, trial design issues and safety issues need to be addressed. This meeting will be unique in that it will bring all the important and relevant parties to the table to discuss these critical issues that will need to be resolved before substantial progress can be made in delivering the next generation of therapeutic agents to affected individuals with chronic hepatitis B and D.

  • Product not yet rated Contains 2 Component(s)

    Joint webinar organized by the AASLD and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN).

    There has been a recent worldwide identification, first from the United Kingdom then globally including the United States, of an unidentified pathogen leading to a plausible increase in cases of severe acute hepatitis in children. Some of these cases have been linked to Adenovirus Type 41, but many questions remain. Of the important etiopathogenesis questions the following will be posed, specifically: 1)Are these cases an increase over prior years? 2) Are these cases all related to the same pathogen? 3)Is there any possible connection to SARSCov2 past infections?

    These and other similarly topical, time-sensitive, and relevant questions will be addressed by this joint webinar organized by the AASLD and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN).

  • Product not yet rated Contains 1 Component(s)

    Webinar hosted by the AASLD COVID-19 Task Force's Clinical Oversight and Education Subcommittee on Wednesday, April 13.

    The AASLD COVID-19 Task Force's Clinical Oversight and Education Subcommittee presents a new installment in its popular COVID-19 and the Liver webinar series. We will begin by covering the therapeutics and pathways to treat outpatients with COVID-19. This will be followed by an overview of the epidemiology of transplant donors and recipients with COVID-19 and an open discussion with a distinguished panel of experts. The expert roundtable discussion will cover the difficult issues surrounding the management of liver transplant donors and recipients who test positive for SARS-CoV-2. Are we using enough of these controversial organs or are we taking unreasonable risks? What really is the risk of donor to recipient disease transmission? What other issues do we need to consider before we accept a SARS-CoV-2 positive donor or recipient? Bring your questions and challenge the panel or just listen in to this exciting and informative webinar.

  • Contains 2 Component(s) Recorded On: 03/15/2022

    Webinar hosted by the Portal Hypertension: Clinical and Experimental Special Interest Group on Tuesday, March 15, 2022.

    This webinar will address endovascular management of portal hypertensive complications using TIPS. Speakers will assess evidence for the use of TIPS in the setting of portal and mesenteric vein thromboses and how this may impact portal HTN, survival, as well as transplant outcomes. Speakers will also discuss the standard and emerging indications for TIPS as well as future directions for TIPS management in portal HTN.

    Virginia Hernandez-Gea

    Virginia Hernández-Gea, MD, PhD is a interventional hepatologist at the liver unit at hospital clinic. She is fully dedicated to the management of patients with portal hypertension and vascular liver diseases as well as conducting liver catheterization procedures including TIPS. She also runs a translational laboratory focused on the understanding of the role of the liver endothelium in liver diseases.

    Dr. Hernández-Gea is a member of the EASL Governing Board and author of more than 120 publications. She has serves as editorial boar member of Hepatology and Liver international. She is currently member of the Portal Hypertension Special Interest Group for the American Association for the Study of Liver Diseases (AASLD), Secretary of VALDIG  (Vascular Liver Disease Interest Group) and faculty of Baveno. As an active teacher and educator, she has directed 5 doctoral thesis and is assistant professor at the university of Barcelona.

    Riad Salem

    Riad Salem, MD, MBA is Professor of Radiology, Surgery and Medicine, Vice-Chair, Image-Guided Therapy and Section Chief, Interventional Radiology in the Department of Radiology at Northwestern University in Chicago. His areas of interest include the use of image-guided techniques for the treatment of liver cancer including chemoembolisation, bland embolization and radioembolisation. He is a graduate of McGill University in Montreal, where he was recipient of the Wood Gold Medal and J Francis Award in Internal Medicine. He then completed his residency in Washington DC, a fellowship in interventional radiology (University of Pennsylvania), as well as a Master’s in Business Administration (Finance).

    Dr. Salem is a member of Alpha Omega Alpha medical honor society and a Fellow of the Society of Interventional Radiology. He has delivered >800 lectures nationally and internationally, and written extensively on the subject of interventional oncology and portal hypertension (TIPS), with over 370 publications, 28000 citations, and an h index of 92. His current research focus on: 1) hepatocellular carcinoma advances in minimally invasive therapies, 2) imaging methodologies following locoregional treatment, and 3) treatment of portal vein thrombosis in cirrhotics and non-cirrhotic using novel TIPS techniques, with conversion of untransplantable patients to transplant candidacy. He serves as PI of two, international, randomized phase III trials involving sorafenib +/- Y90 in HCC (STOP-HCC) and chemotherapy +/- Y90 in CRC (EPOCH); EPOCH was the first large-scale RCT to meet its endpoints in the field of interventional oncology. He was also lead investigator in LEGACY, the pivotal trial that lead to the FDA’s first PMA device approval.

    Elizabeth Verna (Moderator)

    Elizabeth Verna, MD, MS is an Associate Professor of Medicine in the Center for Liver Disease and Transplantation and Division of Digestive and Liver Diseases at Columbia University, where she practices as transplant hepatologist. In addition, Dr. Verna has an active clinical research program in end-stage liver disease and liver transplantation and is the Director of Clinical Research for the Columbia University Transplant Clinical Research Center.